Vinflunine plus capecitabine for advanced breast cancer previously treated with or resistant to anthracycline and resistant to taxane: A phase III study versus capecitabine.

被引：0

作者：

Aapro, Matti S.

Demidchik, Yuri

Bondarenko, Igor

Siedakov, Igor

Sakaeva, Dina

Krishnamurthy, S.

Roman, Laslo

Lebedeva, Liudmila

Mefti, Fawzia

Ponomarova, Olga

Bachelot, Thomas Denis

Lytvyn, Lryna

Delaloge, Suzette

Kupp, Anita

Karchmit, Yauheniya

Bougnoux, Philippe

Campone, Mario

Martin, Miguel

机构：

[1] Clin Genolier, Genolier, Switzerland

[2] Belarusian Med Acad Postgrad Educ, Minsk, BELARUS

[3] Dnipropetrovsk City Multifield Clin Hosp 4, Dnepropetrovsk, Ukraine

[4] Reg Antitumor Ctr, Donetsk, Ukraine

[5] Republican Clin Oncol Dispensary, Ufa, Russia

[6] Kidway Mem Inst Oncol, Bangalore, Karnataka, India

[7] Leningrad Reg Oncol Dispensary, St Petersburg, Russia

[8] Clin Oncol Dispensary, Arkhangelsk, Russia

[9] Hop Rene Huguenin, Inst Curie, St Cloud, France

[10] City Oncol Hosp, Kiev, Ukraine

[11] Ctr Leon Berard, Dept Oncol Med, F-69373 Lyon, France

[12] Reg Oncol Hosp, Dnepropetrovsk, Ukraine

[13] Inst Cancerol Gustave Roussy, Villejuif, France

[14] North Estonia Med Ctr, Tallinn, Estonia

[15] Reg Clin Oncol Dispensary, Vitebsk, BELARUS

[16] CHU Bretonneau, Dept Med Oncol, F-37044 Tours, France

[17] Inst Cancerol Ouest, Nantes, France

[18] Hosp Univ Gregorio Maranon, Madrid, Spain

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期

关键词：

D O I：

10.1200/jco.2014.32.15_suppl.1013

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1013

引用

页数：1

共 50 条

[21] Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer
Miller, KD
Chap, LI
Holmes, FA
Cobleigh, MA
Marcom, PK
Fehrenbacher, L
Dickler, M
Overmoyer, BA
Reimann, JD
Sing, AP
Langmuir, V
Rugo, HS
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (04) : 792 - 799
[22] Phase II Study of the Halichondrin B Analog Eribulin Mesylate in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane, and Capecitabine
Cortes, Javier
Vahdat, Linda
Blum, Joanne L.
Twelves, Chris
Campone, Mario
Roche, Henri
Bachelot, Thomas
Awada, Ahmad
Paridaens, Robert
Goncalves, Anthony
Shuster, Dale E.
Wanders, Jantien
Fang, Fang
Gurnani, Renuka
Richmond, Elaine
Cole, Patricia E.
Ashworth, Simon
Allison, Mary Ann
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (25) : 3922 - 3928
[23] Phase II study of irinotecan plus capecitabine in patients with anthracycline and taxane pretreated metastatic breast cancer
Lee, K. S.
Ro, J.
Park, I. H.
Kim, E. A.
Nam, B.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[24] Ixabepilone plus capecitabine improves overall survival in symptomatic patients with metastatic breast cancer previously treated with anthracycline and taxane in 2 large phase III studies.
Conte, P.
Roche, H.
Perez, E.
Sparono, J.
Xu, B.
Jassem, J.
Peck, R.
Mukhopadhyay, P.
Hortobagyi, G.
CANCER RESEARCH, 2009, 69 (02) : 381S - 382S
[25] The PROCEED trial KCSG BR11-01: Phase III multicenter randomized open label study of irinotecan plus capecitabine versus capecitabine in patients previously treated with anthracycline and taxane for HER2 negative metastatic breast cancer
Park, I. H.
Lee, K. S.
Im, S-A
Jung, K. H.
Park, K. H.
Im, Y-H
Lee, S.
Kim, Y. J.
Kim, H-J
Lee, S.
Lee, M. H.
Kim, T-Y
Lee, K-H
Kim, S-B
Ahn, J-H
Nam, B-H
Ro, J.
CANCER RESEARCH, 2013, 73
[26] A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes
M. Campone
N. Isambert
E. Bourbouloux
H. Roché
J. Bonneterre
G. Milano
P. Fumoleau
Cancer Chemotherapy and Pharmacology, 2012, 69 : 871 - 879
[27] A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes
Campone, M.
Isambert, N.
Bourbouloux, E.
Roche, H.
Bonneterre, J.
Milano, G.
Fumoleau, P.
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (04) : 871 - 879
[28] Capecitabine and mitomycin C is an effective combination for anthracycline- and taxane-resistant metastatic breast cancer
Massacesi, Cristian
La Cesa, Annalisa
Marcucci, Fabiana
Pilone, Alberta
Rocchi, Marco B. L.
Zepponi, Laura
Santini, Daniele
Tonini, Giuseppe
Burattini, Luciano
ONCOLOGY, 2006, 70 (04) : 294 - 300
[29] The PROCEED trial KCSG BR11-01 phase III multicenter randomized open-label study of irinotecan plus capecitabine versus capecitabine in patients previously treated with anthracycline and taxane for HER2 negative metastatic breast cancer
Park, I. H.
Im, S-A
Jung, K. H.
Sohn, J. H.
Park, Y. H.
Park, K-H
Nam, B-H
Kim, J. H.
Kim, H-J
Lee, S.
Kim, T-Y
Lee, K-H
Kim, S-B
Lee, K. S.
Ro, J.
CANCER RESEARCH, 2017, 77
[30] Vinorelbine plus platinum compared to vinorelbine plus capecitabine in treatment of patients with metastatic triple negative breast cancer previously treated with anthracycline and taxane: a prospective randomized study
El-Zawahry, Heba Mohamed
Gaber, Ayman Abd Al-Samie
Abou-Bakr, Amany Abd-Elhameed
Abd-Elhafez, Marwa Nabil
El-Debawy, Ahmed Mohamed
ONCOLOGY IN CLINICAL PRACTICE, 2024, 20 (01): : 1 - 8

← 1 2 3 4 5 →